These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11994895)

  • 1. How to define treatment success using cholinesterase inhibitors.
    Thal LJ
    Int J Geriatr Psychiatry; 2002 Apr; 17(4):388-90. PubMed ID: 11994895
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug therapy of Alzheimer's disease].
    Sulkava R
    Duodecim; 2000; 116(24):2867-73. PubMed ID: 12077892
    [No Abstract]   [Full Text] [Related]  

  • 3. Donepezil in the treatment of mild to moderate Alzheimer's disease: report of a Belgian multicenter study.
    Santens P; Ventura M
    Acta Neurol Belg; 2003 Sep; 103(3):159-63. PubMed ID: 14626696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drugs for Alzheimer disease: what will the minister decide].
    Verhey FR; Scheltens P
    Tijdschr Gerontol Geriatr; 1998 Dec; 29(6):278-9. PubMed ID: 9894324
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanisms of action of Alzheimer medications].
    Alhainen K
    Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
    [No Abstract]   [Full Text] [Related]  

  • 8. The cognitive effects of cholinesterase inhibitor treatment in every-day practice.
    Kapaki E; Paraskevas GP
    Curr Med Res Opin; 2005 Jun; 21(6):871-5. PubMed ID: 15969887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
    Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
    Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dementia].
    Diehl RR
    Fortschr Neurol Psychiatr; 2003 Nov; 71(11):617-28. PubMed ID: 14608514
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease--time to act is now.
    de Silva HA
    Ceylon Med J; 2005 Mar; 50(1):1-4. PubMed ID: 15881555
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy.
    Rozzini L; Vicini Chilovi B; Bellelli G; Bertoletti E; Trabucchi M; Padovani A
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):547-51. PubMed ID: 15920713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
    Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O
    Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy in Alzheimer disease].
    Kovács T
    Orv Hetil; 2004 Apr; 145(17):925-8. PubMed ID: 15170971
    [No Abstract]   [Full Text] [Related]  

  • 17. Cholinesterase inhibitors: relating pharmacological properties to clinical profiles: Introduction.
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):1-5. PubMed ID: 12139364
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
    Connelly PJ; Prentice NP; Fowler KG
    Int J Geriatr Psychiatry; 2005 Jul; 20(7):623-8. PubMed ID: 16021654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticholinesterases in the treatment of Alzheimer's dementia--the first year's experience in Argyll & Clyde.
    Hughes A; Coulter F; Gillespie R; Livingston H; Phillips K; Quinn E; Rimmer E; Smith M; Walker A
    Health Bull (Edinb); 2000 Jan; 58(1):20-4. PubMed ID: 12813848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.